This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna's (MRNA) Coronavirus Vaccine Shows 94.5% Efficacy Rate
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine candidate mRNA-1273 proves its vaccine efficacy of 94.5% in the late-stage COVE study. The stock appreciates in pre-market trading following this news.
J&J (JNJ) Expands BARDA Deal for COVID-19 Vaccine Development
by Zacks Equity Research
J&J's (JNJ) ENSEMBLE study on its COVID-19 vaccine candidate is expected to enroll 60,000 adult participants.
Vaccine Hopes Push Markets To Frothy Levels: Stocks To Watch
by Daniel Laboe
There is now a more defined light at the end of this pandemic tunnel. Still, we are not out of the woods yet.
Pharma Stock Roundup: PFE Coronavirus Data, FDA Emergency Tag for LLY COVID-19 Drug
by Kinjel Shah
Eli Lilly (LLY) and Pfizer (PFE) provide updates on their coronavirus vaccine/antibody candidates.
3 Reasons to Bet on Healthcare ETFs
by Sanghamitra Saha
The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.
AstraZeneca's (AZN) Calquence Fails in Coronavirus Study
by Zacks Equity Research
AstraZeneca's (AZN) BTK inhibitor drug Calquence fails to achieve the main goal in the phase II CALAVI studies for patients hospitalized with respiratory symptoms of COVID-19.
Moderna (MRNA) Up on Coronavirus Vaccine Candidate Progress
by Zacks Equity Research
Moderna ((MRNA) is set for the first interim analysis of its late-stage coronavirus vaccine study. Positive data may support an emergency use authorization by the end of 2020. Stock up.
AstraZeneca's (AZN) Asthma Drug Meets Primary Goal in Phase III
by Zacks Equity Research
AstraZeneca's (AZN) pipeline candidate tezepelumab achieves the primary goal in phase III NAVIGATOR study for addressing patients with severe, uncontrolled asthma.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson
Vaccine Hopes Rise as Pharma Giants Inch Closer Toward Success
by Ritujay Ghosh
Stocks of Eli Lilly and Company (LLY), Pfizer, Inc. (PFE) and Moderna, Inc. (MRNA) have been in focus since the coronavirus outbreak as they have been the frontrunners in the vaccine race.
Pfizer COVID-19 Vaccine Data Raises Hopes for Industry, Economy
by Kinjel Shah
Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 90% effective in phase III.
Positive News on COVID-19 Vaccine
by Zacks Equity Research
Positive News on COVID-19 Vaccine
Pfizer's Covid Drug Proves 90%+ Effective; PFE, BNTX
by Mark Vickery
A Covid vaccine takes the lid off most everything market-related. That said, we're still looking at a period of months before it would be widely available.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Emergent (EBS) Beats on Q3 Earnings, Tapers '20 Sales View
by Zacks Equity Research
Emergent (EBS) beats on earnings in Q3 while revenues miss estimates. Total product sales fall year over year and the company tightens its revenue guidance. Stock slides in after-hours trading.
Ironwood (IRWD) Q3 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter.
AstraZeneca (AZN) Q3 Earnings Miss Estimates, Sales Beat
by Zacks Equity Research
AstraZeneca (AZN) lags Q3 earnings estimates and surpasses the same for sales. It maintains its financial outlook for the year.
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J
What's in Store for Emergent (EBS) This Earnings Season?
by Zacks Equity Research
On Emergent's (EBS) upcoming third-quarter earnings call, investors will focus on the company's recent CDMO collaborations to help partners manufacture a vaccine against COVID-19.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) third-quarter results are expected to reflect the impact of new drug sales.
Moderna (MRNA) Q3 Earnings Lag Estimates, Pipeline Advances
by Zacks Equity Research
Moderna (MRNA) reports wider-than-expected third-quarter loss. However, revenues beat estimates significantly. Shares up presumably on encouraging pipeline progress and rising cash resources.
Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study
by Kinjel Shah
Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results
Novo Nordisk's (NVO) Q3 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.
Update on the COVID Vaccine Race
by John Blank
A 2021 Macro Recovery is About This, Alone.